Major League Baseball that Padres outfielder Cameron Maybin has been suspended for 25 games, effective immediately. Maybin has violated the Joint Drug Prevention and Treatment Program by testing positive for amphetamines, and will not receive pay.
Maybin issued a statement through the MLBPA (Major League Baseball Players Association) on his suspension:
“I have been undergoing treatment for several years for a medical condition, attention deficit disorder, for which I previously had a Therapeutic Use Exemption. Unfortunately, in my attempts to switch back to a medicine that had been previously OK’d, I neglected to follow all the rules and as a result I tested positive. I want to assure everyone that this was a genuine effort to treat my condition and I was not trying in any way to gain an advantage in my baseball career. I understand that I must accept responsibility for this mistake and I will take my punishment and will not challenge my suspension. I apologize to my family, friends, fans, teammates and the entire Padres organization. I look forward to returning to the field and contributing to the success of my club.”
It’s yet another blow to what’s been an impotent San Diego squad. The team has struggled mightily this season, so much so that General Manager Josh Byrnes was dismissed. Closer Huston Street and third baseman Chase Headley have been traded away, with more moves almost certainly on the way. Coming into Wednesday’s action, they’ve only hit .215 as a group.
Maybin was once a heralded top prospect. He was the focal point of the trade that brought Miguel Cabrera and Dontrelle Willis to Detroit in 2007, but never truly panned out. He came to San Diego in 2010 in another trade.
Maybin is a career .248/.309/.370 hitter, over parts of eight seasons.
For more on sports injuries, check out our friends at Sports Injury Alert.
Thank you for reading. Please take a moment to follow me on twitter @StelliniTweets, and our department, @MLBFB. Support LWOS by following us on Twitter – @LastWordOnSport – and “liking” our Facebook page.
Main Photo:
